Table 1.
Details of various patient, disease, and treatment characteristics in the long-term survivors.
| Feature | Long-Term Survivors (n = 97) |
|---|---|
| Age | |
| <60 years | 69 (71%) |
| 60 years or more | 28 (29%) |
| Gender | |
| Male | 23 (24%) |
| Female | 74 (76%) |
| ECOG (during diagnosis of BM) | |
| 0–1 | 73 (75%) |
| 2 or more | 13 (14%) |
| Unknown | 11 (11%) |
| Number of intracranial lesions (at time of BM diagnosis) | |
| Single | 63 (65%) |
| Multiple | 34 (35%) |
| Primary | |
| Lung | 51 (52%) |
| Breast | 24 (25%) |
| Thyroid | 6 (7%) |
| Melanoma (skin) | 5 (5%) |
| Kidney | 3 (3%) |
| Unknown primary | 3 (3%) |
| Gynecological malignancies | 2 (2%) |
| Male genitourinary | 1 (1%) |
| Gastrointestinal | 1 (1%) |
| Head neck | 1 (1%) |
| Extracranial disease status (at the time of BM diagnosis) | |
| Controlled | 38 (39%) |
| Uncontrolled | 59 (61%) |
| Interval from cancer diagnosis to detection of BM | |
| Median (range) | 15 (0–266) months |
| First site of metastasis | |
| Brain | 74 (76%) |
| Others | 23 (24%) |
| Molecular characteristics | |
| Targetable mutations | |
| Yes | 38 (39%) |
| No | 51 (53%) |
| Unknown | 8 (8%) |
| Hormonal receptors (among patients with breast cancer) | |
| Yes | 16 (67%) |
| No | 8 (33%) |
| Unknown | 8 (8%) |
| Systemic therapy a | |
| Targeted therapy/Hormonal therapy/Immune therapy | 64 (66%) |
| None of the above/Unknown | 33 (34%) |
| Stereotactic radiosurgery a | |
| Yes | 50 (52%) |
| No | 47 (48%) |
| Whole brain radiotherapy a | |
| Yes | 54 (56%) |
| No | 43 (44%) |
| Surgery a | |
| Yes | 39 (40%) |
| No | 58 (60%) |
ECOG: Eastern cooperative oncology group; BM: Brain metastasis. before, during, or after diagnosis of brain metastasis. a intracranial treatment at the time of initial diagnosis of brain metastasis.